Search | Clinical Trials Finder

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: Ivabradine, Ivabradine Placebo, Coordinated Care, Usual Care; Drug · Behavioral
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Eczema, Atopic Dermatitis
Interventions: Sodium chloride tablets, Placebo Tablets; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Type 2 Diabetes
Interventions: ertugliflozine, low salt diet, placebo, high salt diet; Drug · Behavioral
Lead sponsor: Amsterdam UMC, location VUmc; Other
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Salt-sensitive Hypertension
Interventions: Valsartan, LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Anaheim, California • Cypress, California • Glendale, California

Conditions: Infection, Human Immunodeficiency Virus
Interventions: 744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Intraabdominal Infections
Interventions: Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: San Diego, California • Springfield, Massachusetts

Conditions: Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions: Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal; Drug · Radiation · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: DTG 50 mg, RPV 25 mg, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: Metabolic Syndrome, Insulin Sensitivity, Cardiovascular Diseases
Interventions: Phosphorus-supplemented study diet, Control Diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions: tolvaptan, placebo matching tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more

Conditions: Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions: Alteplase, Unfractionated heparin, Placebo, Apixaban; Drug
Lead sponsor: Victor Tapson, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Psoriasis
Interventions: Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cognition
Interventions: Modafinil 200mg, mixed amphetamine salts, Placebo; Drug
Lead sponsor: United States Army Aeromedical Research Laboratory; Federal
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fort Rucker, Alabama

Conditions: Alopecia Areata
Interventions: CTP-543, Placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more

Conditions: Influenza
Interventions: VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Ascites, Cirrhosis
Interventions: Albumin, Intravenous Saline Infusion (Albumin placebo), Midodrine, Oral tablet (Midodrine placebo), Octreotide LAR, Saline injection (Octreotide LAR placebo), Large Volume Paracentesis; Drug · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Healthy
Interventions: amoxicillin 400mg + clovalunic acid 57.5mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: NSCLC
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 43
States / cities: Phoenix, Arizona • Arcadia, California • Duarte, California + 37 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pralatrexate, Erlotinib, Vitamin B12, Folic Acid; Drug · Dietary Supplement
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Bakersfield, California • San Diego, California • Port Saint Lucie, Florida + 12 more

Conditions: Healthy
Interventions: Deferitazole (disodium salt, granule), Deferitazole (disodium salt, tablet), Deferitazole (magnesium hydroxide salt); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bleeding
Interventions: 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: ondansetron, moxifloxacin, saline; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)

The Impact of Dietary Salt on the Severity of Eczema

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

Effect of Phosphorus Additives on the Metabolome in Healthy Adults

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects